An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease

Inclusion Criteria

Patients must have:

* Patients \> 18 months of age with history of positive serology for HIV-1 infection or patients \<= 18 months of age with history of positive viral culture, detectable p24 antigen, or positive peripheral blood mononuclear cell macro culture.

* Patients \>= 13 years of age with a CD4+ cell count \<= 200 cells/mm3. Patients \< 13 years of age with a CD4% \<= 14% or a 50% decrease in CD4% in the past 6 months if the previous CD4% was \>=20%.

* Patient has failed or is intolerant to currently approved treatments for HIV-1 infection and is unable to participate in a controlled viramune clinical trial.

* Written and informed consent from a parent or guardian for patients \< 18 years of age.

* Patient or guardian is willing and able to follow protocol requirements. (PER AMENDMENT 1/29/97:

* Enrollment is closed to adults, as of Jan. 29th only pediatric patients will be enrolled.)

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms and conditions are excluded:

Patient qualifies for participation in an actively accruing Viramune controlled clinical trial.

Concurrent Medication:

Excluded:

* Dicumarol, Warfarin, and other anticoagulant medications.

* Tolbutamide.

* Investigational drugs, all protease inhibitors, and all other non-nucleoside transcriptase inhibitors.

* Neurotoxic drugs.

* Cimetidine.

* Erythromycin.

Required:

Patient has failed or is intolerant to currently approved treatments for HIV-1 infection.